We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program

News   Feb 13, 2012

 
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program
 
 
 

RELATED ARTICLES

B Cells May Be More Important in Immunotherapy Than Previously Thought

News

Researchers have found evidence that B cells might play an important role in immunotherapy for melanoma. Currently, immunotherapy is primarily focused on T cells, but the results suggest that B cells could also provide an interesting research avenue.

READ MORE

Some Cancer Drugs Don’t Work by Hitting Their Targets

News

Some cancer drug candidates in clinical trials kill cancerous cells through off-target effects instead of by interacting with their intended molecular targets, according to new study findings.

READ MORE

Delivering Flecks of Precious Metal to Cancer Cells

News

Scientists have found a way to dispatch minute fragments of palladium inside cancerous cells. The metal could be used to aid cancer treatments.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE